Skip to contentN
NovoCure Ltd
N
NVCRNovoCure Ltd Q1 2022 · 10-Q
Revenue$137.55M$137.55M+2.1% vs Q1 2021 Net Income-$4.65M-$4.65MN/M vs Q1 2021 EPS Diluted-$0.04-$0.04N/M vs Q1 2021 Gross Profit$109,820,000+1.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
NovoCure Ltd · CIK 1645113 · Engraved from SEC EDGAR
Operating Cash Flow-$3,687,000N/M Free Cash Flowderived-$8,780,000N/M Margins · derivedGross margin79.8%−0.6 pt vs Q1 2021
Operating margin-0.6%−0.5 pt vs Q1 2021
Net margin-3.4%−0.3 pt vs Q1 2021
ended Mar 31, 2022 · filed Apr 28, 2022 · 28 d after period end